A new targeted drug for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug that targets a common gene change (RAS) in advanced pancreatic cancer. It combines that drug with other treatments to see if it helps people whose cancer has not responded to or come back after prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your pancreatic cancer is advanced (spread or cannot be removed with surgery) and has a change in the RAS gene.
- You have had at least one prior treatment for advanced pancreatic cancer (for one part of the study) or at most one prior treatment (for other parts).
- You are able to get out of bed and take care of yourself (ECOG score 0 or 1).
- You do not have serious infections, fluid buildup that cannot be controlled, or untreated blockages in your bile ducts or bowels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
This trial tests a new combination treatment for pancreatic cancer that has spread or cannot be removed with surgery. The goal is to see if the combination can help control the cancer and is safe.
This trial tests a new drug combination for people whose pancreatic cancer has grown after their first treatment. The goal is to see if it can help shrink tumors or slow the disease.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.